Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ Total Current Assets
All assets expected to be converted to cash or used up within one year.
Equillium, Inc.NASDAQ: EQ
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 284.0% from a year ago
Total current assets stood at $62.28M at the end of Q1 FY2026, up 284.0% from a year earlier and up 105.7% from the prior quarter. Over 3 fiscal years it compounded at -26.7% a year.
Context
- Total current assets amounted to 98.7% of total assets at the end of Q1 FY2026, up 1.8 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +284.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 30.28M USD
- Year-over-year change
- +21.2%
- 4-year CAGR
- -22.4%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.28M | +21.2% |
| FY2024 | 2024-12-31 | 24.98M | -49.4% |
| FY2023 | 2023-12-31 | 49.35M | -35.7% |
| FY2022 | 2022-12-31 | 76.74M | -8.0% |
| FY2021 | 2021-12-31 | 83.37M | — |
Total Current Assets vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's Mar 2026 total current assets of $62.28M is the 3rd highest of the 10 companies compared; the peer median is $20.9M.
- Its year-over-year change of +284.0% is the 2nd highest of 10, against a peer median of +27.0%.
- Total current assets amounts to 98.7% of total assets for EQ, versus a peer median of 82.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $295.48M | +132.8% | -18.7% | 82.8% | |
| Mar 2026 | $139.04M | -18.0% | -27.7% | 42.6% | |
| Mar 2026 | $62.28M | +284.0% | -26.7% | 98.7% | |
| Mar 2026 | $55.03M | +80.0% | -14.6% | 98.0% | |
| Mar 2026 | $26.39M | +65.7% | -21.7% | 85.5% | |
| Mar 2026 | $20.9M | +17.4% | -14.2% | 95.5% | |
| Mar 2026 | $7.36M | +1.4% | -29.9% | 61.8% | |
| Mar 2026 | $5.91M | +27.0% | +23.1% | 29.9% | |
| Mar 2026 | $5.79M | +1078.7% | +432.1% | 100.0% | |
OSTXOS Therapies Incorporated | Mar 2026 | $917.55K | -77.6% | -12.5% | 12.6% |
| Peer median (excluding EQ) | $20.9M | +27.0% | -14.6% | 82.8% | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 50.37M | 59.11M | 23.22M | 18.09M | 30.28M |
| Short-term Investments | 30.35M | 11.92M | 17.65M | 4.49M | 0 |
| Net Receivables | 0 | 4.11M | 6.29M | 1.14M | 108K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 8K | 235K | 429K | (547K) |
| Total Current Assets | 83.37M | 76.74M | 49.35M | 24.98M | 30.28M |
| Property, Plant & Equipment (Net) | 1.88M | 1.58M | 1.11M | 626K | 658K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 153K | 104K | 70K | 0 | 0 |
| Total Non-current Assets | 2.04M | 1.69M | 1.18M | 626K | 658K |
| Total Assets | 85.41M | 78.42M | 50.53M | 25.6M | 31.89M |
| Account Payables | 1.23M | 3.98M | 4.71M | 2.68M | 755K |
| Short-term Debt | 1.43M | 5.71M | 0 | 197K | 363K |
| Tax Payables | 0 | 0 | 0 | 365K | 0 |
| Deferred Revenue | 0 | 14.7M | 15.73M | 0 | 0 |
| Other Current Liabilities | 3.38M | 0 | 3.64M | 2.68M | 1.82M |
| Total Current Liabilities | 8.92M | 32.04M | 27.57M | 6.36M | 2.93M |
| Long-term Debt | 8.75M | 3.24M | 0 | 0 | 356K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 10.38M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 9.99M | 14.44M | 384K | 187K | 356K |
| Total Liabilities | 18.9M | 46.48M | 27.96M | 6.54M | 3.29M |
| Common Stock | 2K | 3K | 3K | 3K | 5K |
| Retained Earnings | (109.98M) | (172.41M) | (185.74M) | (193.81M) | (216.21M) |
| Accumulated OCI | (138K) | 76K | 140K | 781K | 363K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 66.51M | 31.94M | 22.57M | 19.06M | 28.6M |
| Total Debt | 11.79M | 10.19M | 824K | 384K | 719K |
| Net Debt | (38.58M) | (48.92M) | (22.39M) | (17.7M) | (29.56M) |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.